Initiation of clinical studies with SL-701, a synthetic multi-peptide vaccine with enhanced immunostimulatory properties targeting multiple glioma-associated antigens, in adults with first recurrence of glioblastoma
Initiation of clinical studies with SL-701, a synthetic multi-peptide vaccine with enhanced immunostimulatory properties targeting multiple glioma-associated antigens, in adults with first recurrence of glioblastoma. SNO 2014.
